Cytokinetics Stock

Cytokinetics Dividend

Dividend of Cytokinetics (CYTK) as of Aug 17, 2026.

Dividend

0.00USD

Last updated:

How much dividend does Cytokinetics 2026 pay?

According to the latest status from August 2026, Cytokinetics paid a total of 0.00 USD per share in dividends within the last 12 months. With the current Cytokinetics price of 74.13 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Cytokinetics Dividends

PaydateDividend

Is the Cytokinetics Dividend Safe?

Cytokinetics has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Cytokinetics's Dividend Distributions

Cytokinetics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Cytokinetics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Cytokinetics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Cytokinetics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Cytokinetics Stock analysis

What does Cytokinetics do? Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytokinetics stock

Cytokinetics paid dividends every year for the past 0 years.

Cytokinetics is assigned to the 'Health' sector.

The dividends of Cytokinetics are distributed in USD.

Dividend calendar 2026
Access this data via the Eulerpool API
Get Free API Key

All Key Metrics — Cytokinetics